Benzene Exposure Linked to Acute Myeloid Leukemia: Mechanisms and Evidence

From General Health to Occupational Focus

The legacy of general health and science information has long provided a foundation for public understanding of environmental influences on well-being. Within this broad context, discussions of chemical exposures and their potential health consequences have been a recurring theme, often framed in terms of everyday risk communication and preventive awareness. This heritage emphasizes the importance of recognizing how substances encountered in daily life may interact with biological systems, without delving into specific pathological mechanisms. As this informational landscape evolves, a natural pivot occurs toward more specialized domains, particularly occupational health. The transition from general health literacy to focused workplace concerns is marked by a shift in perspective: from population-level awareness to the concentrated exposures experienced by workers in specific industries. In this regard, benzene—a widely used industrial solvent and component of petroleum products—emerges as a substance of particular interest. Occupational settings such as chemical manufacturing, petroleum refining, and rubber production present scenarios where inhalation or dermal contact with benzene may occur at levels exceeding those found in the general environment. This bridge from general health context to occupational exposure concern sets the stage for examining the relationship between benzene and acute myeloid leukemia risk. The focus now narrows to the professional environments where sustained contact with this compound raises important questions about long-term health outcomes, moving beyond broad informational heritage into a targeted inquiry relevant to industrial hygiene and worker safety.

Benzene as a Carcinogen: Evidence for AML Causation

Benzene is a well-established myelotoxin and a recognized risk factor for the development of acute myeloid leukemia (AML). Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms, and it is acknowledged as able to augment the risk for the onset of AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Furthermore, a meta-analysis of childhood cancers found an increased risk of AML associated with benzene exposure, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Mechanisms of Benzene-Induced Leukemogenesis

The mechanisms by which benzene initiates hematological tumors are multifaceted. Possible mechanisms include a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action (MOA) for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Occupational Exposure and Risk Context

In a national cohort from Switzerland, occupational exposure to benzene was found to be associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). This study assessed occupational exposure by applying a quantitative benzene job-exposure matrix (BEN-JEM) to census-reported occupations (https://pubmed.ncbi.nlm.nih.gov/38727681/). The findings reinforce the link between benzene and AML in occupational settings. From a clinical perspective, patients with AML typically present with symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts. For patients with a history of benzene exposure, the timeline between exposure and documented health outcomes can vary. The key events in the MOA for benzene-induced AML include hematotoxicity and genetic toxicity, which can be observed in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). These early events may precede the development of MDS or AML by years. The risk of AML increases with cumulative exposure, and occupational exposure at levels of 10 ppm or more has been specifically associated with increased risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). In a safety-communication context, it is important to convey that benzene is a known human carcinogen and that chronic exposure, even at relatively low levels, can increase the risk of AML. The evidence from epidemiological studies and mechanistic research supports a causal relationship. For affected patients, a causation-focused clinical interpretation should consider the intensity and duration of benzene exposure, as well as the presence of early hematologic abnormalities. The incorporation of key event information, such as hematotoxicity and genetic toxicity, should modify the risk model for benzene-induced AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). In summary, benzene exposure is causally linked to AML through multiple mechanisms, including genotoxicity, oxidative stress, inflammation, and immunosuppression. Occupational exposure at levels of 10 ppm or more increases AML risk, and childhood exposure is also associated with elevated odds of AML. The timeline from exposure to disease can involve years, with early key events detectable in peripheral blood. These findings underscore the importance of minimizing benzene exposure in occupational and environmental settings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the evidence linking benzene exposure to acute myeloid leukemia?

Benzene is a well-established myelotoxin and recognized risk factor for AML. Chronic exposure can increase risk for AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure at levels of 10 ppm or more has been associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). A meta-analysis of childhood cancers found an odds ratio of 1.22 per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

What are the mechanisms by which benzene causes leukemia?

Benzene initiates hematological tumors through multiple mechanisms including genotoxic effects, oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action includes early key events such as hematotoxicity and genetic toxicity in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.